| Nome |
# |
|
New therapeutic targets in pancreatic cancer, file e2f56ed8-ef81-3eaf-e053-3a05fe0a5d97
|
1.038
|
|
Immunotherapy associated pulmonary toxicity: Biology behind clinical and radiological features, file e2f56ed8-0bdb-3eaf-e053-3a05fe0a5d97
|
736
|
|
Clustered protocadherins methylation alterations in cancer, file e2f56ed8-c7b7-3eaf-e053-3a05fe0a5d97
|
682
|
|
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis, file e2f56ed6-8569-3eaf-e053-3a05fe0a5d97
|
534
|
|
ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib, file e2f56ed8-7dab-3eaf-e053-3a05fe0a5d97
|
503
|
|
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients, file e2f56ed5-2bb2-3eaf-e053-3a05fe0a5d97
|
426
|
|
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression, file e2f56ed9-9d7e-3eaf-e053-3a05fe0a5d97
|
417
|
|
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials, file e2f56ed8-b6c4-3eaf-e053-3a05fe0a5d97
|
396
|
|
Molecular classifications of gastric cancers: Novel insights and possible future applications, file e2f56ed7-2196-3eaf-e053-3a05fe0a5d97
|
393
|
|
null, file e2f56ed5-2859-3eaf-e053-3a05fe0a5d97
|
376
|
|
Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer, file e2f56ed8-9a5b-3eaf-e053-3a05fe0a5d97
|
364
|
|
Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: Training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier), file e2f56ed8-b6bb-3eaf-e053-3a05fe0a5d97
|
362
|
|
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS study, file e2f56ed5-28ce-3eaf-e053-3a05fe0a5d97
|
350
|
|
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma, file e2f56ed5-285e-3eaf-e053-3a05fe0a5d97
|
327
|
|
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced hcc patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group, file e2f56ed5-28d0-3eaf-e053-3a05fe0a5d97
|
317
|
|
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: A retrospective study, file e2f56ed6-8533-3eaf-e053-3a05fe0a5d97
|
317
|
|
Lactate dehydrogenase in hepatocellular carcinoma: something old, something new, file e2f56ed5-2c11-3eaf-e053-3a05fe0a5d97
|
297
|
|
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment, file 8ebc3cb7-4c88-4c30-befb-60bceaf06aed
|
275
|
|
Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab, file e2f56ed4-40e6-3eaf-e053-3a05fe0a5d97
|
253
|
|
Immunotherapeutic approaches for hepatocellular carcinoma, file e2f56ed6-8b44-3eaf-e053-3a05fe0a5d97
|
233
|
|
Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management, file e2f56ed4-f9f3-3eaf-e053-3a05fe0a5d97
|
213
|
|
Gold nanoparticles: A new golden Era in oncology?, file e2f56ed9-a939-3eaf-e053-3a05fe0a5d97
|
202
|
|
Molecular-biology-driven treatment for metastatic colorectal cancer, file e2f56ed9-4e0d-3eaf-e053-3a05fe0a5d97
|
182
|
|
Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma, file e2f56ed5-28c7-3eaf-e053-3a05fe0a5d97
|
171
|
|
Rare histotypes of epithelial biliary tract tumors: A literature review, file 7bd3d417-d8d1-4143-a033-e9258488eb70
|
161
|
|
Prognostic value for incidental antihypertensive therapy with β-blockers in metastatic colorectal cancer, file e2f56ed4-429f-3eaf-e053-3a05fe0a5d97
|
157
|
|
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management, file e2f56ed4-4e6d-3eaf-e053-3a05fe0a5d97
|
155
|
|
BRAF-mutant colorectal cancer, a different breed evolving, file e2f56ed8-5249-3eaf-e053-3a05fe0a5d97
|
149
|
|
Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients, file e2f56ed4-4107-3eaf-e053-3a05fe0a5d97
|
137
|
|
The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment, file e2f56ed4-4199-3eaf-e053-3a05fe0a5d97
|
133
|
|
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib, file e2f56ed4-42aa-3eaf-e053-3a05fe0a5d97
|
127
|
|
Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach, file e2f56ed4-4a50-3eaf-e053-3a05fe0a5d97
|
127
|
|
The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management, file e2f56ed4-410f-3eaf-e053-3a05fe0a5d97
|
125
|
|
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab, file e2f56ed4-48f6-3eaf-e053-3a05fe0a5d97
|
123
|
|
Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients, file e2f56ed4-42af-3eaf-e053-3a05fe0a5d97
|
120
|
|
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib, file e2f56ed6-21ff-3eaf-e053-3a05fe0a5d97
|
120
|
|
No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC), file e2f56ed6-830f-3eaf-e053-3a05fe0a5d97
|
115
|
|
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis, file e2f56ed5-3093-3eaf-e053-3a05fe0a5d97
|
112
|
|
Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer, file e2f56ed8-10c4-3eaf-e053-3a05fe0a5d97
|
110
|
|
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology, file e2f56ed6-ba5a-3eaf-e053-3a05fe0a5d97
|
108
|
|
From central to sentral (Serum angiogenesis central): Circulating predictive biomarkers to anti-VEGFR therapy, file e2f56ed9-ac71-3eaf-e053-3a05fe0a5d97
|
107
|
|
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib, file e2f56ed9-b6f8-3eaf-e053-3a05fe0a5d97
|
106
|
|
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm?, file a634f0fb-0fbc-40ea-874e-ee41d1bd267b
|
104
|
|
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression, file 8126a541-a33e-4b36-947c-ec40fe88ca5c
|
100
|
|
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab, file e2f56eda-62d3-3eaf-e053-3a05fe0a5d97
|
98
|
|
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis, file ecb7a96a-1b3f-468d-a246-459af97f201e
|
97
|
|
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?, file e2f56ed9-4bd8-3eaf-e053-3a05fe0a5d97
|
96
|
|
Health related quality of life in patients with onco-hematological diseases, file e2f56ed9-6b04-3eaf-e053-3a05fe0a5d97
|
87
|
|
Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study, file e2f56eda-924a-3eaf-e053-3a05fe0a5d97
|
77
|
|
Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the “CARACAS” study, file 0a789e29-56d9-4880-bfe9-fd6082f69d39
|
72
|
|
Colorectal cancer promoter methylation alteration affects the expression of glutamate ionotropic receptor AMPA type subunit 4 alternative isoforms potentially relevant in colon tissue, file e2f56eda-719d-3eaf-e053-3a05fe0a5d97
|
63
|
|
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients, file e2f56eda-bd0b-3eaf-e053-3a05fe0a5d97
|
56
|
|
Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer, file cf82eb11-44e6-4087-be44-6acc7659440e
|
51
|
|
The role of fetal programming in human carcinogenesis - May the Barker hypothesis explain interindividual variability in susceptibility to cancer insurgence and progression?, file 7ff92b55-0103-42d3-8d15-6ec203def5ec
|
47
|
|
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples, file e2f56eda-4342-3eaf-e053-3a05fe0a5d97
|
45
|
|
Primary Tumor Resection for Metastatic Colorectal, Gastric and Pancreatic Cancer Patients: In Search of Scientific Evidence to Inform Clinical Practice, file 3db65eca-ca66-4c7b-8596-7975915bd94a
|
44
|
|
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib, file e2f56ed9-5b18-3eaf-e053-3a05fe0a5d97
|
41
|
|
Immune Checkpoint Inhibitors in the Treatment of HCC, file e2f56eda-9def-3eaf-e053-3a05fe0a5d97
|
41
|
|
Laparoscopic management of isolated nodal recurrence in gynecological malignancies is safe and feasible even for large metastatic nodes up to 8 cm: A prospective case series, file 2b2746e2-8824-4584-afba-1715a44e0483
|
39
|
|
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158), file e2f56ed9-eb00-3eaf-e053-3a05fe0a5d97
|
34
|
|
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib, file edfe971a-b125-4e72-9c46-4e1db1eea374
|
30
|
|
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment, file 4480f1a7-7551-4012-8578-67fdfd7d60d2
|
26
|
|
The Difficult Task of Diagnosing Depression in Elderly People with Cancer: A Systematic Review, file 05e96b0e-8a56-466c-b839-5e82eea376b3
|
25
|
|
Survival trends over 20 years in patients with advanced cholangiocarcinoma: Results from a national retrospective analysis of 922 cases in Italy, file b48f671b-9456-47da-9d14-d5fb1b470ad2
|
24
|
|
Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis, file 55532d45-5c88-4426-9c9a-ebdfa8f5db0c
|
22
|
|
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors, file 9dd2e0c7-2148-4e4b-b971-b3f8b5a092b8
|
21
|
|
Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers, file e2f56eda-5b87-3eaf-e053-3a05fe0a5d97
|
21
|
|
Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice, file e2f56eda-7cb4-3eaf-e053-3a05fe0a5d97
|
21
|
|
Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members, file f66d2587-4d50-4a9d-be10-febcd8b5bf24
|
21
|
|
Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma, file e2f56eda-5c59-3eaf-e053-3a05fe0a5d97
|
20
|
|
The Reliability and Test-Retest Stability of the Treatment Perception Questionnaire (TPQ) in the Oncology Field: A Pilot Study, file e2f56eda-ac25-3eaf-e053-3a05fe0a5d97
|
18
|
|
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib, file e2f56ed4-4ea8-3eaf-e053-3a05fe0a5d97
|
17
|
|
How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world, file e2f56eda-d69d-3eaf-e053-3a05fe0a5d97
|
15
|
|
Pathogenic and Prognostic Roles of Paraneoplastic Leukocytosis in Cervical Cancer: Can Genomic-Based Targeted Therapies Have a Role? A Literature Review and an Emblematic Case Report, file 4f2d4ec2-644b-4f29-bbf0-5c70dc923036
|
14
|
|
The Innate Immune Microenvironment in Metastatic Breast Cancer, file c1e48fbe-7c7e-4d0d-92ea-01ae8555b05b
|
14
|
|
The association between Major Depressive Disorder and premature death risk in hematologic and solid cancer: a longitudinal cohort study, file e2f56ed9-bcc1-3eaf-e053-3a05fe0a5d97
|
14
|
|
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not?, file 216bdc66-524c-4ce5-afd1-8c8058d391fe
|
13
|
|
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab, file 4f6f63bc-9843-4c9a-b908-40a76d3380d1
|
13
|
|
The Quality of Life of People with Solid Cancer is Less Worse than Other Diseases with better Prognosis, Except in the Presence of Depression, file e2f56eda-4437-3eaf-e053-3a05fe0a5d97
|
13
|
|
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: The CARACAS study, file e2f56eda-7530-3eaf-e053-3a05fe0a5d97
|
13
|
|
Infections in lung cancer patients undergoing immunotherapy and targeted therapy: an overview on the current scenario, file 22bc02b0-b8fe-458b-87df-6f8de4a0c7ea
|
12
|
|
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment, file e2f56eda-5bf0-3eaf-e053-3a05fe0a5d97
|
12
|
|
Adherence to treatment in patients with solid and hematological cancers. Could spiritual and psychological support facilitate optimal adherence?, file 845cd91e-29bc-4e13-8e22-884d467d2844
|
11
|
|
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib, file cb652948-468c-4b23-b693-8eb51f809b06
|
11
|
|
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study, file e2f56ed8-3f6e-3eaf-e053-3a05fe0a5d97
|
11
|
|
Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients, file bb161a49-a058-4e6a-acfd-638cc3948a84
|
10
|
|
null, file 22ea06ba-10a2-4145-bfd5-c3979ea35895
|
9
|
|
Timing of the negative effects of trastuzumab on cardiac mechanics after anthracycline chemotherapy, file e2f56ed5-cd3c-3eaf-e053-3a05fe0a5d97
|
9
|
|
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey, file e2f56eda-7cac-3eaf-e053-3a05fe0a5d97
|
9
|
|
Low adherence to therapy and co-morbid depressive episodes are independent determinants of early death in people with cancer, file 1b308f47-84ea-4e3a-b59a-5e6f789f085e
|
8
|
|
Cancer cachexia and chronic inflammation: an unbreakable bond, file 589e8939-526f-4c4a-a859-4b791ec9f308
|
8
|
|
Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?, file e2f56ed5-285b-3eaf-e053-3a05fe0a5d97
|
8
|
|
Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world, file e2f56ed6-836b-3eaf-e053-3a05fe0a5d97
|
8
|
|
Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: Key role of interleukin-6, file e2f56ed7-cd11-3eaf-e053-3a05fe0a5d97
|
8
|
|
Fused deep learning paradigm for the prediction of o6-methylguanine-DNA methyltransferase genotype in glioblastoma patients: A neuro-oncological investigation, file 63ed1bc8-f7a4-4c26-bf46-e79c152d8e68
|
7
|
|
Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario, file 811dcf38-c2cc-4ed8-8f71-7e6daa1ff76f
|
7
|
|
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients, file a9017d32-0194-4c20-82fa-8d909d31e6ed
|
7
|
|
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research, file e2f56ed5-6683-3eaf-e053-3a05fe0a5d97
|
7
|
|
Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma, file e2f56ed6-83c1-3eaf-e053-3a05fe0a5d97
|
7
|
|
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy, file e2f56ed8-5fc3-3eaf-e053-3a05fe0a5d97
|
7
|
| Totale |
13.399 |